Cencora (COR) AI Stock Analysis

• Market Cap: $65.89B
• Dividend Yield: 0.67%
• Average Volume (3M): 1.58M
• Price to Earnings (P/E): 42.7
• Beta (1Y): 0.06
• Revenue Growth: 9.31%
• EPS Growth: 5.92%
• Country: US
• Employees: 42,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 3.84
• Shares Outstanding: 193,993,440
• 10 Day Avg. Volume: 1,619,954
• 30 Day Avg. Volume: 1,584,640
• PEG Ratio: 4.19
• Price to Book (P/B): 24.06
• Price to Sales (P/S): 0.11
• P/FCF Ratio: 11.31
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 0.20
• Enterprise Value/Gross Profit: 5.73
• Enterprise Value/Ebitda: 23.83
• 1Y Price Target: $394.40
• Price Target Upside: 16.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 17.66
• Revenue Forecast (FY): $340.70B

• Rating: 65 Neutral
• Price Target: $363.00 ▲(7.45% Upside)

Cencora's overall stock score is driven by strong financial performance and positive earnings call sentiment, indicating a solid growth outlook. However, technical indicators suggest bearish momentum, and the high P/E ratio raises valuation concerns. Corporate events provide additional support through strategic financial flexibility.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability.

Strategic Investments

Investments in infrastructure enhance operational capacity and competitive positioning, fostering sustainable growth.

Financial Flexibility

Enhanced financial flexibility allows for better capital management and strategic investments, supporting long-term growth initiatives.

Negative Factors

High Leverage

High leverage increases financial risk and can limit the company's ability to invest in growth opportunities, impacting long-term stability.

Goodwill Impairment

Significant goodwill impairment indicates challenges in business segments, potentially affecting profitability and strategic focus.

Net Interest Expense

Rising interest expenses can strain cash flows, reducing funds available for reinvestment and impacting financial health.

Cencora Business Overview & Revenue Model

Company Description

Cencora (COR) is a global healthcare services company that specializes in providing integrated solutions across the pharmaceutical supply chain. The company operates in various sectors, including logistics, clinical trial management, and patient support services. Cencora's core offerings include the distribution of pharmaceuticals, management of clinical trials, and supply chain solutions tailored to the needs of biopharmaceutical companies and healthcare providers.

How the Company Makes Money

Cencora generates revenue through multiple streams, primarily by charging fees for its logistics and distribution services, which include warehousing, transportation, and inventory management of pharmaceuticals. The company also earns revenue from its clinical trial management services, where it partners with biopharmaceutical companies to facilitate the testing and approval of new drugs. Additionally, Cencora offers patient support services that help patients access medications, which further contributes to its revenue. Strategic partnerships with major pharmaceutical companies enhance its market reach and stability, providing a steady flow of contracts and projects that bolster earnings.

Cencora Financial Statement Overview

Summary

Cencora demonstrates solid revenue growth and cash flow generation, but faces challenges with high leverage and relatively low margins. The company needs to focus on improving operational efficiency and managing its debt levels to enhance financial stability.

Income Statement

Cencora has shown consistent revenue growth over the years, with a slight dip in net profit margin in the latest year. The gross profit margin has improved slightly, indicating better cost management. However, the EBIT and EBITDA margins are relatively low, suggesting room for improvement in operational efficiency.

Balance Sheet

The company has a high debt-to-equity ratio, which poses a risk in terms of financial leverage. However, the return on equity has improved significantly, indicating better utilization of equity. The equity ratio is low, suggesting a heavy reliance on debt financing.

Cash Flow

Cencora's cash flow position is strong, with significant growth in free cash flow. The operating cash flow to net income ratio indicates efficient cash generation relative to net income. The free cash flow to net income ratio is robust, showing good cash conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	321.33B	321.33B	293.96B	262.17B	238.59B	213.99B
Gross Profit	11.48B	11.48B	9.91B	8.96B	8.30B	6.94B
EBITDA	2.76B	3.60B	2.18B	3.37B	3.47B	3.41B
Net Income	1.55B	1.57B	1.51B	1.75B	1.70B	1.54B
Balance Sheet
Total Assets	76.59B	76.59B	67.10B	62.56B	56.56B	57.34B
Cash, Cash Equivalents and Short-Term Investments	4.36B	4.36B	3.13B	2.59B	3.39B	2.55B
Total Debt	7.66B	7.66B	4.39B	4.79B	5.70B	6.68B
Total Liabilities	74.84B	75.08B	66.46B	62.04B	56.49B	56.75B
Stockholders Equity	1.75B	1.51B	645.94M	522.00M	-289.78M	223.35M
Cash Flow
Free Cash Flow	3.21B	3.21B	3.00B	845.86M	2.21B	2.23B
Operating Cash Flow	3.88B	3.88B	3.48B	1.30B	2.70B	2.67B
Investing Cash Flow	-4.98B	-4.98B	-618.10M	-2.60B	-368.44M	-6.14B
Financing Cash Flow	2.25B	2.25B	-2.33B	-2.22B	-1.75B	1.95B

Cencora Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 337.82
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COR, the sentiment is Neutral. The current price of 337.82 is below the 20-day moving average (MA) of 358.95, below the 50-day MA of 339.09, and above the 200-day MA of 298.16, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 39.15 is Neutral, neither overbought nor oversold. The STOCH value of 11.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COR.

Cencora Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSIC	74 Outperform	$8.67B	23.26	11.39%	―	3.51%	29.65%
PDCO	70 Outperform	―	―	―	―	-0.85%	-23.40%
CAH	66 Neutral	$47.24B	30.01	―	1.02%	4.37%	28.48%
COR	65 Neutral	$65.89B	42.66	144.31%	0.67%	9.31%	5.92%
MCK	62 Neutral	$99.81B	25.17	―	0.38%	17.23%	66.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMI	42 Neutral	$200.33M	―	-184.47%	―	-37.09%	-2639.44%

Cencora Corporate Events

Cencora Reports Strong Q4 Revenue Growth and Dividend Increase

On November 5, 2025, Cencora reported its fiscal 2025 fourth quarter and year-end results, highlighting a 5.9% increase in fourth-quarter revenue to $83.7 billion and a 9.3% rise in annual revenue to $321.3 billion. Despite a GAAP diluted EPS loss of $1.75 in the fourth quarter, the adjusted EPS increased to $3.84. The company also raised its quarterly dividend by 9% and its long-term guidance, reflecting confidence in continued growth driven by strategic acquisitions and a focus on digital transformation. These results underscore Cencora’s strengthened position in the healthcare market and its commitment to driving stakeholder value.

Cencora Amends Credit Agreements for Enhanced Flexibility

On September 5, 2025, Cencora, Inc. amended its Term Credit Agreement, originally dated November 26, 2024, to adjust the maturity date to October 1, 2027, and modify the interest rate structure based on public debt ratings. Additionally, Cencora amended its Money Market Facility Agreement to allow borrowings up to $750 million during certain periods, enhancing its financial flexibility. These amendments are likely to impact Cencora’s operational strategies and financial positioning, offering greater adaptability in managing its credit facilities.